Eisai, Biotoscana ink exclusive licensing pact for Latin America

Under the terms of the agreement, Eisai grants Biotoscana an exclusive license to seek regulatory approvals and commercialize the anticancer agents Halaven and Lenvima, as well as antiepileptic agents Fycompa and Inovelon in Latin America. In Mexico, however, Eisai will retain the rights to, and conduct all activities for, Halaven and Lenvima. Eisai Inc. will supply Biotoscana with the products, for which it will receive compensation, and is also entitled to a one-time payment as well as milestone payments.

Biotoscana is a pharmaceutical company operating out of 10 countries in Latin America, where it is developing a strong portfolio that includes oncology products. As a result of granting Biotoscana these licenses, Eisai can swiftly expand access in Latin American markets for its innovative new drugs, and further contribute to patients in Latin America.

Eisai positions oncology and neurology as key therapeutic areas. By accelerating the development of its innovative new drugs in these areas and pursuing optimal business models to match regional characteristics, Eisai seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients and their families all over the world.

Eisai, biotoscana ink exclusive licensing pact, latin america